Market Signals

BP, Shell and Chevron restoring U.S. Gulf oil production after hurricane

Buy the dip on this satellite stock as catalysts line up, says Deutsche Bank

S&P Global: This Moat Is On Sale

A month ago (Sept 14), Trump did the same thing, randomly announcing a ceasefire that neither side knew anything about.

Citizens Financial: Increasing Profit Makes 7.3% Preferred Dividend Yield Safer

Book is -7.5% to -6.1%, only 1.4 points. Thin short signal. Median conf 77 does not change that. Dominant driver is illiquidity, 4 of 10. Drag is mome

UnitedHealth Q3 earnings in focus as investors look for top-line growth

The S&P 500 short scan is a rates and crowding trade, not a sector call. Earnings yield vs bonds is the dominant drag in 6 of 10. Every name sits in t

North Korea fires 'several ballistic missiles' into Sea of Japan, Seoul's military says

The scan is leaning hard on earnings yield vs bonds. It drives 7 of 10. Short interest and 60d vol are the next tells. Financials and Consumer Defensi

I told ChatGPT to ‘continue’ — it went too far

The scan is thin: 6m expected returns only -4.7% to -3.3%, median conf 73. That 1.4 pt spread says the signal is weak. No single factor owns this list

Book is +4.4% to +5.2%, thin signal even at conf 74. Model weight is earnings yield vs bonds first, then cheap fwd/trail P/E. Dajin Heavy Industry Co.

UK’s Burnham says Russia interfered in Brexit vote

Nikkei 225 quant shorts: earnings yield vs bonds is the dominant driver in 10 of 10. That is the whole scan. Not a stock picker. Consumer Cyclical sup

The NBFC saga - Part 3: How one default in 2018 changed the way RBI reads risk - The Economic Times

The scan is leaning hard on earnings yield vs bonds. That driver prints in 10 of 10 names. Book: +16.8% to +29.3%, median conf 87. Consumer Cyclical h

Andy Burnham says it is clear Russia interfered in Brexit referendum

The Pentagon- and Toyota-backed startup trying to cut US reliance on China iron

A former iPhone LCD plant in Japan is being repurposed to make package substrates, JDI's Mobara factory changing hands for the fifth time, now to Shin

Long scan — China (MCHI) — Sunday, October 11, 2026. BOOK: 6m +7.0%..+8.8%, median conf 91 DOMINANT DRIVER: earnings yield vs bonds in 6 of 10

Marko Kolanovic calls Trump’s energy ceasefire a ‘con,’ Tom Lee sees potential inflation relief

First time the Fed, ECB and BOJ all hiked in the same month, and only the dollar got paid — the index up ~1.2% to a seven-week high. The BOJ's move to

Crude oil prices hit a near three-month high: geopolitical premium drives oil prices higher.

📊 S&P 500 Q3 2026 Earnings Update — Mid-season

$VEEV — hold 📊 | 6 months thesis

$MEDS just filed an S-1/A — but this isn't a classic IPO. DataMeds AI is a Nasdaq-listed Delaware holding company for pharma distribution and healthca

GT Biopharma is filing for an IPO. The clinical-stage immuno-oncology company is developing TriKE, a platform that engineers a patient's own NK cells

Patriot Mobile Inc. just filed for an IPO. The Grapevine, TX-based MVNO resells wireless service on AT&T, T-Mobile and Verizon networks, marketing its

Bambusa Therapeutics ($BBTX) just filed for IPO. Clinical-stage biopharma developing half-life-extended bispecific antibodies for immunology & inflamm

BirchBioMed Inc. (Nasdaq: BRBM) is a UBC spinoff clinical-stage biopharma pursuing a direct listing on Nasdaq — no new capital raised, with registered

Pomdoctor is getting suspended from Nasdaq — trading halts Oct 15, 2026 after failing the minimum bid price requirement. A staff determination letter

Aspen Neuroscience ($ASPE) is seeking a Nasdaq IPO. The clinical-stage biotech is developing sasineprocel, a cell therapy for Parkinson's disease now

DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again

Japan declares cyber space emergency as attacks soar

Trump's memorial arch faces a new lawsuit from Arlington County, Virginia

FingerMotion files an S-1/A amendment. The Nasdaq micro-cap is pivoting from China mobile payments and data analytics to North American enterprise AI

U.S. Economic Growth Expected To Strengthen In Q3 GDP Report

ADC Therapeutics: Shares Spike On Restructuring, But Safety Fears Undermine Bull Thesis

Omada Health Shows Promising Growth But I Question The Moat

Book is tight: +7.4% to +9.1%, median conf 78 — thin edge. Model still leaning hard into 12mo momentum, drives 7 of 10. Raiffeisen Bank International

What to know about Mistral's ML4 as it bets on EU sovereignty in the US-China open-weight AI race

The scan is not picky: 6m expected returns -19.4% to -14.8%, median confidence 91. Common drag is earnings yield vs bonds in 6 of 10 names. Short inte

The scan is paying up for cheapness vs bonds. Earnings yield vs bonds is the top driver in 7 of 10. Every name sits at univ 98-100. This is rank conce

The White House is blocking Microsoft and seven other IT firms from PERM applications — the H-1B-to-green-card pipeline. Vance called it fraud; Labor'

Book is -4.4% to -3.5%—thin signal, median conf 72. Scan says no clean theme: valuation/rates and downside risk split the list. China Three Gorges Ren

City Therapeutics just filed its S-1/A. The RNAi player is developing next-gen therapeutics to silence disease-relevant proteins, with lead candidate

China (MCHI) top 10: book only spans +3.9% to +5.0%, so the edge is thin despite median conf 74. Model weight is in top-decile names: Technology (3),

The scan is one macro short: earnings yield vs bonds is dragging all 10 names. Consumer Cyclical names keep showing up, with Healthcare and Industrial

The EU budget continues delivering for Europe in 2025